1. A spinal midline indicator comprising:
a body of radiolucent material sized and shaped to fit into an intervertebral space between two adjacent vertebrae; and
a radiographic marker formed as an elongated handle attached to and extending from the body along a central axis of the body in an anterior-posterior direction and
at least two secondary radiographic markers on opposite sides of the elongated handle and located equidistant from the elongate handle and from lateral edges of the body.
2. A spinal midline indicator according to claim 1, wherein the handle is made of stainless steel or titanium.
3. A spinal midline indicator according to claim 1, wherein the secondary radiographic markers are embedded in the body.
4. A spinal midline indicator according to claim 1, wherein the body has a length in a direction of the handle which is smaller than a width in a direction perpendicular to the length.
5. A spinal midline indicator according to claim 1, wherein the handle extends substantially through the body.
6. A spinal midline indicator to identify a spinal midline, the indicator comprising:
a body of radiolucent material sized and shaped to fit into an intervetebral space between two adjacent vertebrae; and
a radiographic marker centrally disposed within the body and extending from the body to guide a marking applied to the midline of at least one of the two adjacent vertebrae and
at least two secondary radiographic markers on opposite sides of the elongated handle and located equidistant from the elongate handle and from lateral edges of the body.
7. A spinal midline indicator according to claim 6, further comprising a handle is made of stainless steel or titanium.
8. A spinal midline indicator according to claim 6, wherein the secondary radiographic markers are embedded in the body.
9. A spinal midline indicator according to claim 6, wherein the marker extends substantially through the body.
10. A spinal midline indicator according to claim 1, wherein a central axis of the body is equal distance from each of two lateral edges of the body.
11. A spinal midline indicator according to claim 9, wherein the radiographic marker is disposed equal distance from each of two lateral edges of the body.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of treating, diabetic hyperlipidemia, or hyperlipidemia, comprising
administering a therapeutically effective amount of a compound selected from the group consisting of:
carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester;
carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-1-(4-fluoro-phenyl)-3-oxo-propyl ester;
carbamic acid 3-(4-benzo1,3dioxol-5-yl-piperazine-1-yl)-3-oxo-1-phenyl-propyl ester;
carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-1-(4-trifluoromethyl-phenyl)-3-oxo-propyl ester;
carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-1-(4-nitro-phenyl)-3-oxo-propyl ester;
(R)-carbamic acid 3-4-(4-chloro-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester;
(S)-carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester;
(R)-carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester;
carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-1-phenyl-butyl ester; and
carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-1-(4-chloro-phenyl)-3-oxo-propyl ester,
or a pharmaceutically acceptable salt, isomer, solvate, or hydrate thereof, to a subject in need of treatment.
2. The method of claim 1, wherein the method further comprises a step of identifying a subject in need of the treatment before the administering step.
3. The method of claim 1, wherein the compound is administered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier.
4. The method of claim 3, wherein the pharmaceutically acceptable carrier is microcrystal cellulose.
5. The method of claim 1, wherein the compound is orally administered.
6. The method of claim 1, wherein the pharmaceutically effective amount is about 300 mg.
7. The method of claim 1, wherein the compound is
carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester;
(S)-carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester; or
(R)-carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester.
8. The method of claim 7, wherein the compound is (R)-carbamic acid 3-4-(3,4-dimethoxy-phenyl)-piperazine-1-yl-3-oxo-1-phenyl-propyl ester.